Research Center for Traditional Chinese
Medicine Modernization Recognized for Advancing Quality Control
Authentication and Profiling Methods
Waters Corporation (NYSE: WAT) today welcomed the Shanghai
Institute of Materia Medica’s (SIMM) Research Center for
Modernization of Traditional Chinese Medicine under the direction
of Dr. De-an Guo into the Waters Centers of Innovation (COI)
Program. The Research Center plays a leading role in the effort to
develop standardized methods for analyzing the authenticity and
compositional integrity of traditional medicines and bring them
into compliance with quality standards instituted by the China Food
and Drug Administration (CFDA).
This Smart News Release features multimedia.
View the full release here:
http://www.businesswire.com/news/home/20151021005950/en/
Today in Shanghai, Waters welcomed Dr.
De-an Guo and the Shanghai Institute of Materia Medica into the
Waters Centers of Innovation Program. Pictured (l. to r.) are
Professor Yang Ye, Deputy Director of the Shanghai Institute of
Materia Medica; Dr. De-an Guo, Director - Research Center for
Modernization of Traditional Chinese Medicine, Shanghai Institute
of Materia Medica; Mike Harrington, Vice President, European &
Asia Pacific Operations, Waters Corporation; and Eric Fotheringham,
Director – Waters Centers of Innovation Program, Waters
Corporation. (Photo: Business Wire)
Said Yang Ye, Deputy Director of Shanghai Institute of Materia
Medica, “We are pleased to have our TCM Research Center honored by
Waters for the Centers of Innovation Program, the first in China.
This is a wonderful opportunity for the Center and Waters to work
closely together to tackle the holistic analysis of the complex
Chinese herbal system.”
On hand to congratulate Dr. Guo and his team was Dr. Mike
Harrington, V.P. Asia/Pacific Operations, Waters Division. “We
could not be more excited to be working with Dr. Guo and his fellow
researchers at the Shanghai Institute of Materia Medica,” said
Harrington. “The work of the Institute and the Research Center is
vital to the efforts to globalize Traditional Chinese Medicine and
enlist it in the fight against disease and in the quest to improve
human health.”
Said Eric Fotheringham, Director – Waters Centers of Innovation
Program, "We are particularly pleased to welcome Dr. Guo and his
team into the Waters Centers of Innovation Program, as they are the
first COI Program partner focused upon the challenges of
characterizing TCM related raw materials and manufactured
products."
In his remarks delivered at Wednesday’s ceremony, Brian Smith,
V.P. – Mass Spectrometry Operations, Waters Division, said,
“Through our partnership with Dr. Guo, and by combining analytical
technology with great science, we are helping one another advance
TCM and bring it onto a global stage.”
Now that the CFDA regulates Traditional Chinese Medicines and
related herbal supplements, Dr. Guo’s Research Center for
Modernization of Tradition Chinese Medicine is tasked with
developing standardized quality control test methods for herbal
medicines and bringing them into routine use. Currently, many TCM
quality standards are mostly based on the presence of a single
marker in a sample, but as Dr. Guo points out, this approach is not
without its drawbacks, since an unscrupulous manufacturer could
simply add that single marker into the formulation to falsify the
results and make it look like it is something it really isn’t.
"We’re now using UPLC to profile the whole chemical composition,
and to quantify the multiple active markers, not just a single
marker," said Dr. Guo. "By taking a more holistic approach to
quality control, including fingerprint profiling, multi-component
quantification, testing for pesticides, heavy metals, and microbial
contaminations we can identify whether it is the true herb and
attest to its quality."
To fulfill its mission, the Center uses a variety of
state-of-the art instruments in addition to the Waters® ACQUITY®
UPLC® System. They include the Waters ACQUITY QDa® Mass Detector,
the ACQUITY UPC2® Convergence Chromatography™ system, and a
Xevo® G2-XS QTof mass spectrometer. The Center also relies on
modern informatics platforms, such as the Waters UNIFI® Scientific
Information System to maintain high working efficiency.
Waters officially saluted the work of Dr. Guo and Research
Center for TCM Modernization with a ceremony and three-day
conference organized in part and sponsored by the Waters Centers of
Innovation Program. The 2015 Shanghai International Conference on
Traditional Chinese Medicine and Natural Medicine is featuring
presentations and a panel discussion by more than three dozen
experts in TCM.
Asked what the recognition means to him, Dr. Guo said, “It’s
really an honor and a privilege for Waters to take so much interest
in the work we do. I’m looking at this as an opportunity to deepen
our collaboration and working together on quality monographs for
Chinese herbal medicines for the Chinese pharmacopoeia and others,
such as United States Pharmacopoeia and European
Pharmacopoeia.”
Dr. Guo, as Editor-in-Chief, recently co-authored an article in
the World Journal of Traditional Chinese Medicine in which the
authors document the progress of China’s TCM modernization efforts
and the challenges it still faces.
About Traditional Chinese Medicine
For more than 2,000 years, medicines derived from natural
sources have been a staple of Chinese medical practice. In the late
1990’s, the Chinese government initiated an effort to modernize
TCM. Broadly defined, this effort intends to push for the
acceptance and integration of Chinese medical philosophy into
western medical practice and seek regulatory approval of herbal
medicines to treat disease.
The effort, involving government, pharmaceutical industry and
academic scientists, has resulted in the adoption of over 50 TCM
quality monographs by the United States or European Pharmacopeias.
Several TCM products are also in mid-to-late-stage clinical trials
in the U.S. and Europe.
About the Shanghai Institute of Materia Medica, Chinese
Academy of Sciences
The Shanghai Institute of Materia Medica (SIMM) at the Chinese
Academy of Sciences emerged from the Institute of Materia Medica of
the Peking Academy of Sciences, founded in 1932. By combining basic
and applied research in chemistry and biological disciplines, SIMM
carries out modern drug discovery. SIMM is also involved in the
discovery of new therapeutic targets and carries out comprehensive
pre-clinical evaluation of drug candidates, while also promoting
commercialization, thereby playing a key role in building China's
drug innovation capabilities. For more information, visit
http://www.simm.cas.cn.
About Waters Centers of Innovation Program
Established in 2010, Waters Centers of Innovation Program
recognizes accomplished scientists and their institutions for
research in the fields of the health sciences, pharmaceuticals,
chemical materials, food and environmental chemistry, mass
spectrometry and separations science. By partnering with leading
scientists and connecting them with experts in mass spectrometry
and separations science, Waters endeavors to bring about inspired
thinking that converts ideas into reality.
The participants in the Waters Centers of Innovation Program
include: Professor Ganesh Anand, National University of Singapore;
Professor Luiz Claudio Cameron, UniRio, Brazil; Professor David
Clemmer, Indiana University; Professor Daniel Tsun-Yee Chiu, Chang
Gung University; Dr. Joseph Dalluge, University of Minnesota; Dr.
Petur Weihe Dalsgaard, University of Copenhagen; Professor Marcos
Eberlin, University of Campinas, Brazil; Professor Chris Elliott,
Queen’s University Belfast; Professor John Engen, Northeastern
University; Professor Albert J. Fornace, Jr., Georgetown Lombardi
Comprehensive Cancer Center; Professor David Goodlett and Dr.
Maureen Kane, University of Maryland; Professor De-an Guo, Shanghai
Institute of Materia Medica; Dr. Frank Gonzalez, National Cancer
Institute; Dr. Carlo R. Largiadèr, Dr. Jean-Francois DuFour and Dr.
Martin Fiedler, Inselspital University Hospital, Bern, Switzerland; Professor Julie Leary,
University of California – Davis; Professor Amit Kumar Mandal, St.
John’s Research Institute, Bangalore, India; Professor John McLean,
Vanderbilt University; Professor Arthur Moseley, Duke University;
Professor Jeremy Nicholson, Imperial College London; Dr. Devin
Peterson, University of Minnesota; Associate Professor Jessica
Prenni, Colorado State University; Dr. Serge Rezzi, Nestle
Institute of Health Sciences; Dr. Ryan Rodgers, Future Fuels
Institute, Florida State University; Professor Pauline Rudd,
National Institute for Bioprocessing Research and Training;
Professor James Scrivens, University of Warwick; Professor Vladimir
Shulaev, University of North Texas; Dr. Norman Smith, Kings College
London; Professor Sarah Trimpin, Wayne State University; Professor
Bert van Bavel, Örebro University; Caroline West and Eric
Lesselier, University of Orleans, Orleans, France; and Professor
Vicki Wysocki, The Ohio State University.
About Waters Corporation (www.waters.com)
Waters Corporation (NYSE: WAT) develops and manufactures
advanced analytical and material science technologies for
laboratory dependent organizations. For more than 50 years, the
company has pioneered a connected portfolio of separations science,
laboratory information management, mass spectrometry and thermal
analysis systems.
Waters, ACQUITY, UPLC, UPC2, Xevo, QDa, UNIFI and Convergence
Chromatography are trademarks of Waters Corporation.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20151021005950/en/
Waters Corporation:Brian J. Murphy, +1-508-482-2614Public
Relationsbrian_j_murphy@waters.com
Waters (NYSE:WAT)
Historical Stock Chart
From Apr 2024 to May 2024
Waters (NYSE:WAT)
Historical Stock Chart
From May 2023 to May 2024